Nicholas Mitsiades is an Oncology physician affiliated with University of California, Davis. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics need a complete publication history and a confident author match. We omit them when either check fails. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
- Study of Metformin With Simvastatin for Men With Prostate Carcinoma
Sponsor: Nicholas Mitsiades
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
74.3%Anti-androgens42.1%Nubeqa72%Erleada28%Part D<11 patientsCytochrome P450 17A1 Inhibitor16.9%Abiraterone Acetate100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
22%Corticosteroid22%Prednisone100%Part D≥17 patientsGenitourinary & hormones
3.7%alpha-Adrenergic Blocker3.7%Tamsulosin Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2015–2022 per NIH RePORTER. The latest:
- THE RNA HELICASE EIF4A IS A THERAPEUTIC VULNERABILITY IN TRIPLE-NEGATIVE BREAST CANCER
Baylor College of Medicine
FY2022$200,000U54CA233223 - Combating Highly Aggressive Prostate Cancer: Development of Novel Patient Derived Xenograft Models and Application in Preclinical Studies of Novel Selective Androgen Receptor Degraders
Baylor College of Medicine
FY2021$120,000U54CA233223 - REGULATION OF UVEAL MELANOMA CELL FATE BY THE PKC PATHWAY VIA MITF
Baylor College of Medicine
FY2019$351,691R01CA193321
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Michael Rogawski, MD
University of California, Davis
Christopher Bowlus, MD
University of California, Davis
Emanual Maverakis, MD
University of California, Davis
Carroll Cross, MD
University of California, Davis
Carl June, MD
University of Pennsylvania
Stuart Orkin, MD
Harvard Medical School
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”